Blocking mu-opioid receptors inhibits social bonding in rituals.
mu-opioids
naltrexone
ritual
ritual bonding
social bonding
Journal
Biology letters
ISSN: 1744-957X
Titre abrégé: Biol Lett
Pays: England
ID NLM: 101247722
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
entrez:
14
10
2020
pubmed:
15
10
2020
medline:
29
12
2020
Statut:
ppublish
Résumé
Religious rituals are universal human practices that play a seminal role in community bonding. In two experiments, we tested the role of mu-opioids as the active factor fostering social bonding. We used a mu-opioid blocker (naltrexone) in two double-blind studies of rituals from different religious traditions. We found the same effect across both studies, with naltrexone leading to significantly lower social bonding compared with placebo. These studies suggest that mu-opioids play a significant role in experiences of social bonding within ritual contexts.
Identifiants
pubmed: 33050833
doi: 10.1098/rsbl.2020.0485
pmc: PMC7655482
doi:
Substances chimiques
Receptors, Opioid, mu
0
Naltrexone
5S6W795CQM
Banques de données
figshare
['10.6084/m9.figshare.c.5173251']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20200485Références
Biol Lett. 2020 Oct;16(10):20200485
pubmed: 33050833
Soc Cogn Affect Neurosci. 2016 May;11(5):728-35
pubmed: 26796966
PLoS One. 2014 Feb 20;9(2):e88355
pubmed: 24586315
Adapt Human Behav Physiol. 2018;4(4):400-422
pubmed: 30393594
Neurosci Biobehav Rev. 1980 Winter;4(4):473-87
pubmed: 6258111
Am J Addict. 2009 Sep-Oct;18(5):356-62
pubmed: 19874153
Sci Rep. 2018 Feb 27;8(1):3693
pubmed: 29487405
Evol Hum Behav. 2007 Sep;28(5):365-374
pubmed: 21874104
Proc Biol Sci. 2018 May 30;285(1879):
pubmed: 29794040
Emotion. 2011 Apr;11(2):262-6
pubmed: 21500895
Commun Integr Biol. 2011 Nov 1;4(6):735-8
pubmed: 22446541
Biol Lett. 2010 Feb 23;6(1):106-8
pubmed: 19755532
Biol Lett. 2015 Oct;11(10):
pubmed: 26510676
J Altern Complement Med. 2012 Jul;18(7):662-7
pubmed: 22830969
Psychoneuroendocrinology. 2020 Mar;113:104559
pubmed: 31911348
Evol Hum Behav. 2016 Mar 1;37(2):152-158
pubmed: 27158219
Neuroimage. 2016 Sep;138:242-247
pubmed: 27238727
Brain Res. 2007 Dec 12;1184:245-53
pubmed: 17976540
Proc Natl Acad Sci U S A. 2017 May 16;114(20):5300-5305
pubmed: 28461468
Mol Pharmacol. 1994 Feb;45(2):330-4
pubmed: 8114680
Drugs. 1988 Mar;35(3):192-213
pubmed: 2836152
Neuropsychopharmacology. 2011 Dec;36(13):2603-15
pubmed: 21881566
Front Psychol. 2014 Sep 30;5:1096
pubmed: 25324805
Psychol Sci. 2009 Jan;20(1):1-5
pubmed: 19152536
Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):11401-11405
pubmed: 30397114
Pers Soc Psychol Rev. 2018 Aug;22(3):260-284
pubmed: 29130838
Soc Cogn Affect Neurosci. 2019 May 31;14(5):471-479
pubmed: 30976797
Proc Natl Acad Sci U S A. 2017 Feb 28;114(9):2361-2366
pubmed: 28193868
Neuropsychopharmacology. 2019 Jan;44(2):295-305
pubmed: 30120410
AAPS J. 2006 Feb 24;8(1):E76-88
pubmed: 16584136
Psychol Sci. 2013 Aug;24(8):1602-5
pubmed: 23740550
J Pharmacol Exp Ther. 1995 Sep;274(3):1263-70
pubmed: 7562497
Front Behav Neurosci. 2014 Dec 12;8:430
pubmed: 25565999